MedTrace Logo

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

NCT00716092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2014-06-27

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo (linagliptin)

once daily for 28 days

DRUG

Placebo (linagliptin)

once daily for 28 days

DRUG

Sitagliptin

100 mg once daily for 28 days

DRUG

Placebo (sitagliptin)

once daily for 28 days

DRUG

Placebo (sitagliptin)

once daily for 28 days

DRUG

Linagliptin

5mg once daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716092 on ClinicalTrials.gov